IOBT IO Biotech Inc.

FDA Catalyst Company
4.79
-0.25  -5%
Previous Close 5.04
Open 4.75
52 Week Low 3.5643
52 Week High 17.88
Market Cap $138,025,129
Shares 28,815,267
Float 13,264,878
Enterprise Value $-40,282,055
Volume 19,610
Av. Daily Volume 45,930
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/30/2021
Cowen & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/30/2021
Jefferies Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/30/2021

Latest News

  1. NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that the Company will be participating in the Jefferies Global Healthcare Conference, to be held June 8-10, 2022, in New York City. Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech will be available to meet with investors in-person on a one-on-one basis throughout the conference.

    Presentation Details
    Date and Time: Wednesday, June 8, 2022 at 8:30 – 8:55 a.m. ET
    Presenter: Mai-Britt Zocca, President & CEO
    Webcast Link: https://wsw.com/webcast/jeff240/iob/1678650

    A webcast replay of the presentation will be available…

    View Full Article
  2. - First Patient Dosed in Proposed Registrational Trial in Melanoma
    - Multiple Sites to be Opened Across the United States, Australia, and Europe|
    - Trial Builds upon Phase 1 / 2 Results Recently Published in Nature Medicine

    NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has dosed the first patient in its Phase 3 IOB-013 / KN-D18 trial (NCT05155254).

    The IOB-013 / KN-D18 trial seeks to evaluate IO Biotech's lead candidate, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, in…

    View Full Article
  3. -- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April --

    -- Announced initiation and dosing of first patient in Phase 2 Trial of IOB102-IOB103 in combination with KEYTRUDA® (pembrolizumab) as first line treatment in multi-arm basket trial --

    -- Strong Balance Sheet with ~$188 million Cash Runway to Support Multiple Data readouts into mid-2024 --

    NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ended March 31, 2022.

    "During our first…

    View Full Article
  4. Part 1: A New Way to Kill Tumors–IO102-IO103 Phase 3 Trial in Combination with Anti-PD-1 in Advanced Melanoma

    Thursday, April 28th @ 12:30pmET

    NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it will be hosting a series of key opinion leader (KOL) webinars. Part 1, entitled "A New Way to Kill Tumors―IO102-IO103 in Combination with Anti-PD-1 in Advanced Melanoma" will be held on Thursday, April 28, 2022 at 12:30pm Eastern Time.

    The webinar will feature presentations from:

    • Alexander Eggermont, MD, PhD (University Medical Center Utrecht, Comprehensive Cancer Center…
    View Full Article
  5. NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has dosed the first patient, in metastatic non-small cell lung cancer (NSCLC), in its Phase 2 IOB-022 / KN-D38 trial (NCT05077709).

    The IOB-022 / KN-D38 trial seeks to evaluate IO Biotech's lead candidate, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, in previously untreated patients with three different tumor types in the first line setting —NSCLC, squamous cell carcinoma of the head and neck (SCCHN), and urothelial bladder cancer (mUBC).

    View Full Article
View All IO Biotech Inc. News